Tag: concord biotech ipo

Concord Biotech possessed six fermentation-based immunosuppressant APIs as of March 31, 2022, including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus. It had a total annual installed fermentation capacity of 1,250 m3 cubic meters for APIs. It has two DSIR (Department of Science and Industrial Research)-approved R&D divisions with a total of 163 people. The…